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water contamination from a single source can result in wide-
spread cases.
Table 1. Outbreak Investigation
Process/
practice
reviews
Changes
DescriptionY N
Infection
Control
Surveillance
 Performed point prevalence
surveys (rectal cultures) and/or
roommate contact tracing after
each MBL-Psa cluster/case;
established weekly rectal
surveillance (week 24 of
outbreak)
Hand hygiene  Reviewed hand hygiene practices;
increased usage of alcohol hand
rub; recommended against
artificial nails/nail extenders
Central line
care
 Relocated CVC flush processes
away from handwashing sink
Housekeeping  Enhanced unit environmental
cleaning; intermittently attempted
sink drain decontamination (1:
1000 ppm sodium hypochlorite);
discontinued use of contaminated
spray cleaner/deodorizer
Equipment
cleaning
 Reviewed and reorganized
processes
Education  Reviewed Standard Practice and
isolation precautions with all
staff; provided ongoing
education/outbreak feedback to
stakeholders
Patient Care  Restricted routine use of
Carbapenems for febrile
neutropenia; discontinued use of
Ciprofloxacin prophylaxis;
discontinued off-service
admissions; initiated private room
accomodation for all
BMT/hematology/ febrile
neutropenic patients; reinforced
sterile water for nebulizers;
discontinued ambient air
nebulizers for patients with
mucositis; continued contact
isolation for presumptive/
confirmed cases
Environmental
Culturing and
Maintenance
 Performed repeated environmental
and water cultures; removed
faucet aerators and sink stoppers;
replaced medication room/staff
washroom sinks, tub, all sink
grout, and one cold water shut-off
valve
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Akins, P.A., Mobley, S.A., Scott, D., Rybicki, L. Cleveland Clinic
Foundation, Cleveland, OH.
Monitoring Bone Marrow Transplant (BMT) patients for fever is
essential assessment data for early recognition of infection. The
current method of monitoring is oral thermometry (OT). How-
ever, a signiﬁcant number of BMT patients experience oral mu-
cositis, making fever monitoring uncomfortable. Mucositis pain
may prevent patients from being able to correctly place the ther-
mometer, affecting the accuracy of the readings. The temporal
thermometer (TT) is an alternative method of assessment. The
purpose of this project is to explore the differences between TT
and OT monitoring in BMT patients and to assess patient comfort
associated with each method. BMT patients receive a myeloblative
chemotherapy regimen prior to transplant. Neutropenia occurs
within 2 to 3 weeks of therapy and is indicated when the neutrophil
count falls below 1000/mm3. Infection is the major cause of mor-
bidity and mortality among BMT patients. During the ﬁrst 3 to 4
weeks following transplantation, most patients will develop a fever.
In 30 to 40%, blood cultures show bacterial pathogens. A fever in
a neutropenic patient is deﬁned as a temperature 	38.0° C. Alter-
native methods of monitoring fever include pulmonary artery mea-
surement, rectal thermometers, tympanic thermometers, and tem-
poral thermometers. The use of pulmonary artery and rectal
thermometry are contraindicated, as any invasive procedure places
a pancytopenic patient at added risk for infection. The tympanic
thermometer readings can vary, depending on instrument place-
ment, making it unreliable for monitoring fever in BMT patients.
To date no studies have examined the use of TT for monitoring
fever in immunocompromised BMT patients. This is a prospective
exploratory study examining the differences between OT and TT
monitoring in BMT patients. Data will be collected 4 times a day
for 4 days from a convenience sample of BMT patients from M50.
Patients will receive usual routine fever monitoring using OT
method and simultaneously will have their temperature monitored
using the TT method. To standardize assessment of mucositis, the
Oral Mucosa Assessment Scale (OMAS) will be completed daily on
each patient. To assess discomfort, the RN or PCNA will ask the
patient to rate the level of comfort-discomfort related to place-
ment, using a 0 to 10 verbal rating scale. This proposal is still in a
data collection phase, and the ﬁndings may direct change for future
practice to beneﬁt future patients.
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NURSING CARE OF THE GRANULOCYTE DONOR FOR PEDIATRIC STEM
CELL TRANSPLANT PATIENTS
Stanton, T.J., Marconi, A.L., Allison, J., Kurtzberg, J. Duke Univer-
sity Hospital, Durham, NC.
Infection continues to be the leading cause of morbidity and
mortality in patients with severe and sustained neutropenia deﬁned
as an Absolute Neutrophil Count of 500/uL. Cesaro et. al (2003)
concludes that “granulocyte transfusion therapy is potentially use-
ful when the severity of the infection and the host’s immunodeﬁ-
ciency make any other antimicrobial therapy ineffectual.” The
Duke Pediatric Blood and Marrow Transplant program uses gran-
ulocyte transfusion therapy for persistently neutropenic patients
with severe infections and for patients who must undergo a second
bone marrow transplant. Donors are required to go through blood
donor questionnaires and blood testing to ensure the safety of both
the donor and the recipient per FDA donor regulations effective
5/25/2005. When possible, a CMV negative donor is selected.
Once a donor is selected (usually a relative of the patient) a double
lumen pheresis catheter is placed for the duration of the donation.
The donor is primed with G-CSF 10 mcg/kg twice weekly. Gran-
ulocytes are harvested by pheresis 14 to 16 hours post G-CSF
dosing, irradiated, divided into 3 doses, and administered IV to the
patient daily  3. With 2 pheresis per week, the recipient receives
granulocytes 6/7 days. Nurse coordinators and staff nurses on the
inpatient transplant unit collaborate to provide the majority of care
and education to the granulocyte donors in order to provide con-
sistency of care for families. The transplant patient’s nurse is
responsible for monitoring and maintaining the pheresis catheter
and for administering G-CSF by injection to the donor. The nurse
must also educate the donor about possible side effects of G-CSF
therapy and granulocyte donation as well as ways to prevent these
side effects. The purpose of this poster will be to (1) educate the
learner about the nurse’s responsibility in caring for the granulo-
cyte donor; (2) describe the standard operating procedure for daily
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